Academic Journal
Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy.
| Τίτλος: | Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy. |
|---|---|
| Συγγραφείς: | Riddles T; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, QLD, Brisbane, Australia., Smith D; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, QLD, Brisbane, Australia., Reid DW; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, QLD, Brisbane, Australia; Lung Inflammation & Infection, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Henderson D; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia., Blanco AJ; Department of Microbiology, Royal Brisbane Women's Hospital, Brisbane, QLD, Australia., Moore V; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia., Wood M; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia., Evans IES; Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, QLD, Brisbane, Australia. Electronic address: ieuan.evans@uq.edu.au. |
| Πηγή: | Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2026 Jul; Vol. 25 (4), pp. 637-642. Date of Electronic Publication: 2026 Mar 18. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101128966 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5010 (Electronic) Linking ISSN: 15691993 NLM ISO Abbreviation: J Cyst Fibros Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam ; New York : Elsevier, c2002- |
| Ιατρικοί όροι (MeSH): | Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/microbiology , Cystic Fibrosis*/complications , Burkholderia Infections*/microbiology , Burkholderia Infections*/drug therapy , Burkholderia Infections*/epidemiology , Burkholderia cepacia complex*/isolation & purification , Burkholderia*/isolation & purification, Indoles/therapeutic use ; Benzodioxoles/therapeutic use ; Quinolones/therapeutic use ; Pyrazoles/therapeutic use ; Pyridines/therapeutic use ; Aminophenols/therapeutic use ; Humans ; Cystic Fibrosis Transmembrane Conductance Regulator ; Drug Combinations |
| Περίληψη: | Introduction: Burkholderia cepacia complex (BCC) comprises 25 species known to cause disease primarily in people with cystic fibrosis (pwCF). Isolation of BCC has major implications for infection control, eradication strategies, morbidity, and lung transplant eligibility. Although not considered part of the BCC, other Burkholderia species are known to cause respiratory disease in pwCF, namely Burkholderia gladioli and Burkholderia pseudomallei. The introduction of CFTR modulator therapy has improved pulmonary outcomes in pwCF, yet little is known about their impact on Burkholderia species acquisition, clearance, or long-term microbiological or clinical outcomes. Method: We reviewed the outcomes of pwCF infected with Burkholderia species (including BCC, B. gladioli, or B. pseudomallei) receiving care in a large CF centre over the past 15 years, spanning the introduction of CFTR modulator therapy. Results: Forty-four pwCF cultured one of these organisms between 2010 and 2025. Ten had only a single isolation with 28 (63.6%) deemed to have chronic infection and 6 (13.6%) exhibiting transient infection defined by having only two positive cultures. Notably, no new Burkholderia species acquisitions occurred after commencement of elexacaftor/tezacaftor/ivacaftor (ETI). The longitudinal incidence rates of chronic infection with Burkholderia species showed a reducing trend from 2017-2025 with rates of spontaneous clearance following ETI appearing similar to background clearance rates prior to modulator therapy. Conclusion: These findings contribute to the evolving understanding of Burkholderia species in the modulator era. While ETI does not eliminate the risk of chronic infection, it may reduce acquisition and support clearance in a subset of pwCF. (Copyright © 2026 The Authors. Published by Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest All authors report no conflicts of interested in relation to the work submitted in this article. |
| Contributed Indexing: | Keywords: Burkholderia cepacia; CFTR modulators; Cystic Fibrosis; Elexacaftor/tezacaftor/ivacaftor |
| Substance Nomenclature: | 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator) 0 (Indoles) 0 (Drug Combinations) 0 (Benzodioxoles) 0 (Quinolones) 0 (Pyrazoles) 0 (Pyridines) 0 (Aminophenols) |
| Entry Date(s): | Date Created: 20260318 Date Completed: 20260730 Latest Revision: 20260730 |
| Update Code: | 20260731 |
| DOI: | 10.1016/j.jcf.2026.03.011 |
| PMID: | 41850964 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-5010 |
|---|---|
| DOI: | 10.1016/j.jcf.2026.03.011 |